Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Esomeprazole Mepha
- Development stage
- Unknown
- Lead developer
- Mepha
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Esomeprazole Mepha is a generic pharmaceutical product developed by Mepha Ltd., a Swiss subsidiary of Teva Pharmaceutical Industries. It contains esomeprazole, the S-enantiomer of omeprazole, which belongs to the class of proton pump inhibitors (PPIs). The drug is primarily indicated for the treatment of gastroesophageal reflux disease (GERD), including the healing of erosive esophagitis and the long-term management of resolved esophagitis to prevent relapse. Mechanistically, esomeprazole is a prodrug that is activated in the acidic environment of the secretory canaliculi of the gastric parietal cell. Once activated, it forms a covalent bond with the H+/K+-ATPase enzyme (the proton pump), leading to the irreversible inhibition of gastric acid secretion. This reduction in acidity allows for the healing of acid-related esophageal and gastric lesions and provides relief from symptoms such as heartburn.
- Brand names
- Esomeprazole Mepha
- Other names
- Esomeprazole magnesiumEsomeprazol Mepha
02
Targets
CYP2C19 (Cytochrome P450 2C19)ATP4B (Potassium-transporting ATPase subunit beta)CYP2C9 (Cytochrome P450 family 2 subfamily C member 9)ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on Esomeprazole Mepha.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Esomeprazole Mepha.